Avacta Group (LON:AVCT) Sets New 52-Week High – Here’s Why

Avacta Group Plc (LON:AVCT)’s share price reached a new 52-week high on Thursday . The company traded as high as GBX 75 and last traded at GBX 72.05, with a volume of 2528796 shares trading hands. The stock had previously closed at GBX 71.90.

Analyst Upgrades and Downgrades

Separately, Peel Hunt reissued a “buy” rating and set a GBX 99 target price on shares of Avacta Group in a research report on Monday, October 13th. One analyst has rated the stock with a Buy rating, According to MarketBeat.com, Avacta Group presently has an average rating of “Buy” and an average price target of GBX 99.

Avacta Group Stock Performance

The company’s fifty day moving average is GBX 61.91 and its 200 day moving average is GBX 45.74. The company has a market capitalization of £294.17 million, a P/E ratio of -4.11 and a beta of 1.12. The company has a current ratio of 1.29, a quick ratio of 4.96 and a debt-to-equity ratio of 52.53.

Avacta Group (LON:AVCT) last released its quarterly earnings data on Tuesday, September 30th. The biotechnology company reported GBX (4.46) EPS for the quarter. Avacta Group had a negative return on equity of 74.00% and a negative net margin of 114.45%. As a group, equities analysts anticipate that Avacta Group Plc will post -9.9011833 earnings per share for the current year.

About Avacta Group

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.

Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).